Calcineurin-targeted therapies eyed for multiple myelomaApril 29, 2016Lymphoma & Plasma Cell Disorders
Low transformation rate in nodular lymphocyte–predominant Hodgkin lymphomaApril 28, 2016Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Bortezomib-based regimen + transplant increased progression-free survival in primary plasma cell leukemiaApril 26, 2016Lymphoma & Plasma Cell Disorders
Dose-escalated blinatumomab plus dexamethasone induced responses in relapsed/refractory DLBCLApril 22, 2016Lymphoma & Plasma Cell DisordersRare Diseases
CUDC-907 enters phase II for relapsed or refractory lymphoma and multiple myelomaApril 12, 2016Lymphoma & Plasma Cell DisordersFollicular Lymphoma
OTX015 dose for lymphoma narrowed in phase 1 studyApril 10, 2016Lymphoma & Plasma Cell DisordersRare Diseases
Guidelines emphasize testing early and often for renal impairment in multiple myelomaApril 5, 2016Lymphoma & Plasma Cell DisordersRare Diseases
FDA approves propylene glycol–free melphalan for multiple myelomaMarch 15, 2016Lymphoma & Plasma Cell Disorders
Idelalisib use halted in six combo therapy trials, FDA announcesMarch 15, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersFollicular Lymphoma
IMWG issues renal impairment recommendations for myeloma patientsMarch 14, 2016Lymphoma & Plasma Cell Disorders
Temsirolimus results in good but short-duration responses in primary CNS lymphomaMarch 14, 2016Neuro-oncologyCNS/Brain CancerLymphoma & Plasma Cell Disorders
Lenalidomide, thalidomide in melphalan regimen yields similar progression-free survivalMarch 14, 2016Lymphoma & Plasma Cell Disorders
Lenalidomide-dexamethasone yields similar PFS as triplet regimens in elderly multiple myeloma patientsMarch 12, 2016Lymphoma & Plasma Cell Disorders
